个性化临床动态预测模型刻画局限期前列腺癌患者预后:CHHiP 3期试验分析
基于 CHHiP 3期试验 3071 例局限期前列腺癌患者,开发联合模型整合重复 PSA 值与基线预后因素预测生化或临床复发。模型预测性能良好,8年内平均 AUC 0.70、Brier 评分 0.10、校准指数 0.048;3年后 PSA<0.23 ng/mL 提示8年复发风险极低。
要点
- 重复 PSA 值联合基线因素可动态预测局限期前列腺癌复发风险。
- 模型8年内平均 AUC 0.70、Brier 评分 0.10、校准指数 0.048。
- 3年后 PSA<0.23 ng/mL 提示8年复发风险极低。
核心结论
- 成功开发联合统计模型预测前列腺癌复发,评估预后因素与纵向 PSA。
- 动态更新的 PSA 信息可改善预后判断,可用于指导随访和治疗管理选择。
研究设计与样本
- 基于 CHHiP 3期试验,纳入 3071 例局限期前列腺癌患者开发临床动态预测联合模型。
- 模型包括重复 PSA 值的混合效应子模型和预测复发的时间-事件风险子模型,调整年龄、肿瘤特征和治疗等基线预后因素。
主要发现
- 发生复发患者基线及随访期间总体 PSA 值普遍更高,复发前2年 PSA 呈指数上升。
- PSA 值及其变化速率可预测复发。
- 模型在8年内不同预测时间点预测性能良好,总体平均 AUC 0.70、平均 Brier 评分 0.10、平均校准指数 0.048;治疗后纵向 PSA 评估累积5年后的预测进一步改善。
- 3年后 PSA<0.23 ng/mL 提示8年复发风险极低。
临床怎么用
- 动态更新的 PSA 信息可改善预后判断,可用于指导随访和治疗管理选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The CHHiP trial assessed moderately hypofractionated radiation therapy in localized prostate cancer. We utilized longitudinal prostate-specific antigen (PSA) measurements collected over time to evaluate and characterize patient prognosis. METHODS AND MATERIALS: We developed a clinical dynamic prediction joint model to predict the risk of biochemical or clinical recurrence. Modeling included repeated PSA values and adjusted for baseline prognostic risk factors of age, tumor characteristics, and treatment received. We included 3071 trial participants for model development using a mixed-effect submodel for the longitudinal PSAs and a time-to-event hazard submodel for predicting recurrence of prostate cancer. We evaluated how baseline prognostic factor subgroups affected the nonlinear PSA levels over time and quantified the association of PSA on time to recurrence. We assessed bootstrapped optimism-adjusted predictive performance on calibration and discrimination. Additionally, we performed comparative dynamic predictions on patients with contrasting prognostic factors and investigated PSA thresholds over landmark times to correlate with prognosis. RESULTS: Patients who developed recurrence had generally higher baseline and overall PSA values during follow-up and had an exponentially rising PSA in the 2 years before recurrence. Additionally, most baseline risk factors were significant in the mixed-effect and relative-risk submodels. PSA value and rate of change were predictive of recurrence. Predictive performance of the model was good across different prediction times over an 8-year period, with an overall mean area under the curve of 0.70, mean Brier score of 0.10, and mean integrated calibration index of 0.048; these were further improved for predictions after 5 years of accrued longitudinal posttreatment PSA assessments. PSA thresholds <0.23 ng/mL after 3 years were indicative of a minimal risk of recurrence by 8 years. CONCLUSIONS: We successfully developed a joint statistical model to predict prostate cancer recurrence, evaluating prognostic factors and longitudinal PSA. We showed dynamically updated PSA information can improve prognostication, which can be used to guide follow-up and treatment management options.
引用
- Parr H, Porta N, Tree AC, et al. A Personalized Clinical Dynamic Prediction Model to Characterize Prognosis for Patients With Localized Prostate Cancer: Analysis of the CHHiP Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 36822374. doi:10.1016/j.ijrobp.2023.02.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。